Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNBELIEVABLE: Novo | History Defined

Manufacturing Site Problems, Not Trial Results, Push Back FDA Decision on Novo's Once-Monthly Hemophilia A Drug Denecimig

FDA's review of Novo's hemophilia A drug denecimig is delayed by manufacturing site issues, not trial data. Launch is now targeted for 2027.

Medical Daily · Oct 5

NVO vs. LLY: Novo’s CEO Says Confidence Is Gone. Lilly Is Winning 7 in 10 New Seniors.

Eli Lilly continues to outpace Novo Nordisk in the weight-loss market, supported by stronger patient growth and market share gains.

Barchart · Oct 5

Knights' kingdom: how Holbrook restored Newcastle's footy soul for new era

The 1997 and 2001 grand finals are ingrained in Newcastle culture. Now, 25 years later, the club is riding a fresh wave of Novocastrian pride.

Newcastle Herald · Oct 3

From analysis to the latest developments in health,
read the most diverse news in one place.

Liver Fat Fell to Normal in 23 of 26 Adults with Obesity in Small Wegovy Post Hoc Analysis

In a small Novo Nordisk analysis, 23 of 26 adults with obesity and excess liver fat reached normal levels on semaglutide. Here is what the numbers do and do not show.

Medical Daily · Oct 3

Participants Taking CagriSema Showed Changed Brain Responses to High-Calorie Food Images in Novo Study as FDA Decision Nears

Novo says brain scans showed CagriSema changed food-cue responses and cut cravings. The data are early, and an FDA decision is expected in late 2026.

Medical Daily · Oct 2

Patients Who Switched from Weight-Loss Shots to the Wegovy Pill Lost 4.1% of Body Weight in Three Months

Early real-world data show that 194 people who switched from GLP-1 shots to the Wegovy pill lost 4.1% of body weight in three months. Here's the catch.

Medical Daily · Oct 2

Novo Nordisk Licenses Experimental Once-Weekly Obesity Pill From China's Hengrui in Deal Worth Up to $2.6 Billion

Novo Nordisk will pay $300 million upfront, and up to $2.6 billion in total, for Hengrui's once-weekly GLP-1/GIP pill, which has not been tested in people.

Medical Daily · Oct 1

Read news from The Economist, FT, and more,
with one subscription

People Who Took Wegovy Pill Instead Of Injection Still Lost Weight, Data Suggests

The real-world study did not establish causality, but the results could mean the pill might help people maintain the weight-loss results they saw after injections.

International Business Times · Sep 30

Eli Lilly vs. Novo: The Hidden Battle Behind the Weight-Loss Platform Reshaping Industries

GLP-1 is a drug platform, not one product. Lilly leads; Novo slips; Pfizer, Amgen, Roche, and AbbVie chase, with pricing, generic and trial risks.

Barchart · Sep 30

Novo Nordisk Increasingly Calls Wegovy Users Customers, Months After FDA Flagged a 'Live Lighter' Pill Ad Claim

STAT reports Novo now markets Wegovy to customers, months after the FDA called a Wegovy pill ad misleading. What cash-pay buyers should check first.

Medical Daily · Sep 30

Retatrutide Diabetes Results, Mounjaro Heart Data, and Wegovy Pill Switching Study Lead EASD 2026 Meeting Opening in Milan

EASD 2026 opens in Milan with retatrutide, Mounjaro heart, and Wegovy pill data due this week. Here is the schedule and what the numbers show.

Medical Daily · Sep 28

Nanexa Stock Skyrockets More Than 100% After Signing Drug Deal With Wegovy Maker Novo Nordisk

Under the deal, Novo gets the right to use PharmaShell in as many as five development programs for peptide-based medicines targeting obesity, type 2 diabetes and other cardiometabolic diseases.

International Business Times · Sep 25

Novo Nordisk Changed the World With Its GLP-1 Weight-Loss Drugs. Now It Wants to Help Cure Baldness.

The Danish pharmaceutical giant that brought the world Ozempic may be ready to start researching a cure for hair loss. From a business perspective, it's a smart move.

Barchart · Sep 25

Viking's Obesity Edge May Be Staying Power, Not Weight Loss

Viking Therapeutics shares jumped 36% after VK2735 maintenance data showed patients kept most weight loss on less frequent dosing, though Phase 3 results and commercial funding remain unresolved.

MarketBeat · Sep 23

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat · Sep 23

Eli Lilly Keeps Pulling Ahead—Can Novo Nordisk Catch Up?

Eli Lilly leads Novo Nordisk in GLP-1 market share and analyst sentiment, while Novo pins hopes on its CagriSema catalyst and pipeline to offset patent-cliff pressure and lawsuits.

Medical Daily · Sep 23

Self-Pay Channels Make Up Half of Wegovy Business and 90% of Pill Demand as Families Weigh Cash Prices

Novo Nordisk says self-pay channels now make up half of its Wegovy business. Here is what cash prices cost families and which coverage options remain.

Fortune · Sep 23

U.S. demand for Novo Nordisk's weight loss drugs is so huge that the Danish central bank just doubled the nation's entire growth forecast

"The growth is mainly due to Novo’s sales and production in the U.S. market at the beginning of this year."

The Economic Times · Sep 22

Ozempic maker Novo Nordisk sets sights on hair-loss market

The condition is part of a list of areas, including addiction and menopause, where Novo sees potential overlap with either its core scientific expertise or the skills it's recently built in selling prescription drugs directly to consumers.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart · Sep 21

Eli Lilly vs. Novo: The Obesity-Drug Battle Is Entering Its Next Round

The obesity drug market is moving to the second phase, and only one appears to be better positioned to lead the second wave.

Fortune · Sep 21

Moderna's Bob Langer and AI pioneer Yann LeCun join board of Cellular Intelligence, bringing AI into medicine via a Parkinson's drug

CI is pairing top AI and biotech minds on its board (plus an advisory role for OpenAI's Fidji Simo) as it tests models on a Novo Nordisk drug.

The Economic Times · Sep 21

Wegovy maker Novo Nordisk faces investor pressure to find growth beyond weight-loss drugs

Facing increased scrutiny, Novo Nordisk must clarify its future strategy outside of its leading weight-loss drug. Investors are advocating diversification into new therapy areas for sustainable growth. With Eli Lilly set to outshine its sales figures this year, analysts suggest a pivot towards developing zenagamtide instead of CagriSema. It is…

Barchart · Sep 18

Novo is Building a Strong Base to Address Unmet Needs in Diabetes and Obesity Drugs

Novo (formerly Novo Nordisk) is partnering with Anthropic to use AI to speed up drug discovery.

Barchart · Sep 16

NVO Stock Alert: What to Know as Novo Partners With Anthropic on Drug Discovery

Novo Nordisk partners with Anthropic on drug discovery. Here’s what the strategic alliance means for NVO shares.

Euronews · Sep 16

Danish pharma giant Novo to use Anthropic’s Claude to advance AI drug discovery

The deal underscores a broader push by drugmakers to integrate AI across research and development to boost new drug discovery.

The Economic Times · Sep 16

Novo partners with Anthropic to speed up drug development with Claude

The Danish drugmaker will initially test Anthropic models and Claude Science in its research and development workflows, and address scientific problems where their joint capabilities can have the greatest impact, they said.

1 2 3 4 5

Coverage From

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.